The Week

US Antimony (UAMY) fell 4.93% this week to close at $4.63, while the S&P 500 slipped 0.08%, leaving UAMY roughly 4.85 percentage points behind. The stock opened Monday around $4.73, dropped to a week-low of $4.44 on Wednesday, then edged higher into Friday’s $4.63 close. That Wednesday low also marked a fresh low within the stock’s 60-day range, whose high of $8.19 dates back to early July.

Volume was mixed: daily average turnover of 5.5m shares sat about 4% below the median, though Friday jumped to 9.1m shares, a sign of late-week churn.

Key Events

Two threads ran through the week’s news. First, on Monday the company confirmed it would participate in the Piper Sandler Growth Frontiers Conference, a schedule item that put management in front of investors. Second, and more substantive, came Thursday: US Antimony reported 97% recovery in metallurgical tests at its Nevada antimony project, a figure that speaks to resource conversion efficiency and addresses a technical checkpoint the market tracks.

Wednesday brought a more promotional item: the company was ranked #2 among the fastest-growing companies in the Dallas/Fort Worth metroplex. On the share-price side, the stock weakened through the news-heavy middle of the week, bottoming Wednesday and steadying into Thursday and Friday.

Analyst Ratings

As of the latest update, all 4 covering analysts rate UAMY a buy, with no hold, underperform, or sell ratings. The consensus rating is strong buy, and the consensus target price of $10.4375 sits about 125% above the spot price of $4.63. Target prices range from $9.000 to $13.500, so dispersion is not trivial. Within its industry, the stock ranks 32nd out of 64. The wide gap between consensus target and spot stands out against a price trading near the lower end of its 60-day range.

The Week Ahead

The US macro calendar is fairly busy next week, with the Richmond Fed composite index on Tuesday 22 September, followed by initial jobless claims and new home sales on Thursday 24 September. For UAMY these matter mainly through risk appetite, as no company earnings or periodic disclosures are scheduled. Next steps on the Nevada metallurgical recovery figure remain the key fundamental item to watch.

In Short

This week stacks a technical validation and a growth ranking against a near-5% share decline. All 4 brokers rate the stock a buy and the consensus target sits above spot, yet the latest PB is around 3.83 and Friday’s fund-flow snapshot showed large-lot money tilting toward net selling. The tension between a constructive analyst view and a weak price leaves the question of whether Nevada progress can convert into tangible follow-through, and whether macro data keep pressuring small caps.

This article is generated by LongbridgeAI from market data, for information only and not investment advice.